209 related articles for article (PubMed ID: 22848683)
1. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
2. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
3. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
4. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
5. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Werner U; Korn M; Schmidt R; Wendrich TM; Tennagels N
Arch Physiol Biochem; 2014 Oct; 120(4):158-65. PubMed ID: 25144413
[TBL] [Abstract][Full Text] [Related]
7. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
9. Proliferative and signaling activities of insulin analogues in endometrial cancer cells.
Aizen D; Sarfstein R; Bruchim I; Weinstein D; Laron Z; Werner H
Mol Cell Endocrinol; 2015 May; 406():27-39. PubMed ID: 25697343
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer.
Blanquart C; Boute N; Lacasa D; Issad T
Mol Pharmacol; 2005 Sep; 68(3):885-94. PubMed ID: 15976035
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer.
Blanquart C; Gonzalez-Yanes C; Issad T
Mol Pharmacol; 2006 Nov; 70(5):1802-11. PubMed ID: 16926280
[TBL] [Abstract][Full Text] [Related]
12. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
13. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
14. Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2.
Chisalita SI; Johansson GS; Liefvendahl E; Bäck K; Arnqvist HJ
J Mol Endocrinol; 2009 Dec; 43(6):231-9. PubMed ID: 19589910
[TBL] [Abstract][Full Text] [Related]
15. Insulin and its analogues and their affinities for the IGF1 receptor.
Varewijck AJ; Janssen JA
Endocr Relat Cancer; 2012 Oct; 19(5):F63-75. PubMed ID: 22420005
[TBL] [Abstract][Full Text] [Related]
16. Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells.
Pagesy P; Fardini Y; Nguyen TT; Lohmann M; Pierre-Eugene C; Tennagels N; Issad T
Arch Physiol Biochem; 2016; 122(2):54-60. PubMed ID: 26707268
[TBL] [Abstract][Full Text] [Related]
17. Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
ter Braak B; Wink S; Koedoot E; Pont C; Siezen C; van der Laan JW; van de Water B
Breast Cancer Res; 2015 Jul; 17(1):97. PubMed ID: 26187749
[TBL] [Abstract][Full Text] [Related]
18. Specific insulin/IGF1 hybrid receptor activation assay reveals IGF1 as a more potent ligand than insulin.
Slaaby R
Sci Rep; 2015 Jan; 5():7911. PubMed ID: 25604425
[TBL] [Abstract][Full Text] [Related]
19. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
Sarfstein R; Nagaraj K; LeRoith D; Werner H
Cells; 2019 Nov; 8(12):. PubMed ID: 31771180
[TBL] [Abstract][Full Text] [Related]
20. Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues.
Lundby A; Bolvig P; Hegelund AC; Hansen BF; Worm J; Lützen A; Billestrup N; Bonnesen C; Oleksiewicz MB
J Appl Toxicol; 2015 Jul; 35(7):842-50. PubMed ID: 25413577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
